ES396175A1 - Phenylethanolamine derivatives - Google Patents

Phenylethanolamine derivatives

Info

Publication number
ES396175A1
ES396175A1 ES396175A ES396175A ES396175A1 ES 396175 A1 ES396175 A1 ES 396175A1 ES 396175 A ES396175 A ES 396175A ES 396175 A ES396175 A ES 396175A ES 396175 A1 ES396175 A1 ES 396175A1
Authority
ES
Spain
Prior art keywords
signifies
formula
hydrogen atom
radical
antipodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES396175A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Original Assignee
CH Boehringer Sohn AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CH Boehringer Sohn AG and Co KG filed Critical CH Boehringer Sohn AG and Co KG
Publication of ES396175A1 publication Critical patent/ES396175A1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedure for the preparation of compounds of the formula **(See formula)** wherein R1 signifies a hydrogen atom or an alcohol or lower alkoxy radical, R2 signifies a hydrogen atom a methyl or ethyl group, R3 signifies a hydrogen atom a methyl group, R4 signifies a hydrogen atom R5 signifies a atom of hydrogen or a hydroxy group and A means a phenyl radical a phenyl radical substituted especially by halogen, lower alcohol, lower alkoxy and/or hydroxy, or a fused bicyclic radical, in which the ring, which is not attached to the aliphatic chain is isocyclic or heterocyclic and is saturated or aromatic in the form of the racemates, optionally of the pairs of diastereoisomeric antipodes, of the pure optically active forms, as well as of the corresponding acid addition salts, characterized in that a compound of the formula is reduced **(See formula)** and by dividing the compounds obtained if desired in the pairs of diastereoisomeric antipodes or in the pure optically active forms, and from the bases of formula I, acid addition salts are prepared. (Machine-translation by Google Translate, not legally binding)
ES396175A 1970-02-25 1971-10-20 Phenylethanolamine derivatives Expired ES396175A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19702008654 DE2008654A1 (en) 1970-02-25 1970-02-25 Ammoathanoldenvate

Publications (1)

Publication Number Publication Date
ES396175A1 true ES396175A1 (en) 1974-04-01

Family

ID=5763256

Family Applications (3)

Application Number Title Priority Date Filing Date
ES388561A Expired ES388561A1 (en) 1970-02-25 1971-02-24 Phenylethanolamine derivatives
ES396174A Expired ES396174A1 (en) 1970-02-25 1971-10-20 Phenylethanolamine derivatives
ES396175A Expired ES396175A1 (en) 1970-02-25 1971-10-20 Phenylethanolamine derivatives

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES388561A Expired ES388561A1 (en) 1970-02-25 1971-02-24 Phenylethanolamine derivatives
ES396174A Expired ES396174A1 (en) 1970-02-25 1971-10-20 Phenylethanolamine derivatives

Country Status (18)

Country Link
AT (3) AT306707B (en)
BE (1) BE763408A (en)
BG (3) BG18856A3 (en)
CH (4) CH568269A5 (en)
CS (3) CS166748B2 (en)
DE (1) DE2008654A1 (en)
ES (3) ES388561A1 (en)
FR (1) FR2081541B1 (en)
GB (1) GB1340407A (en)
IE (1) IE34970B1 (en)
IL (1) IL36269A (en)
NL (1) NL7102432A (en)
NO (1) NO131983C (en)
PL (3) PL82843B1 (en)
RO (3) RO62244A (en)
SE (1) SE377561B (en)
SU (2) SU421181A3 (en)
ZA (1) ZA711204B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791403B (en) * 1978-04-10 1980-05-28 Draco Ab Composition of matter
FI70205C (en) * 1978-05-17 1986-09-15 Degussa FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA L- / 3-HYDROXI-3-PHENYLPROPYL- (2) / - / 3-OXO-PROPYL / AMINER
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE630296A (en) * 1962-03-31

Also Published As

Publication number Publication date
CH568271A5 (en) 1975-10-31
DE2008654A1 (en) 1971-09-09
RO58559A (en) 1975-09-15
IL36269A0 (en) 1971-04-28
RO60182A (en) 1976-08-15
BG18856A3 (en) 1975-03-20
ES396174A1 (en) 1974-04-01
IE34970L (en) 1971-08-25
BG18855A3 (en) 1975-03-20
ZA711204B (en) 1972-10-25
AT306706B (en) 1973-04-25
CH568268A5 (en) 1975-10-31
NO131983C (en) 1975-09-03
BE763408A (en) 1971-08-24
NL7102432A (en) 1971-08-27
FR2081541A1 (en) 1971-12-03
PL82843B1 (en) 1975-10-31
PL84268B1 (en) 1976-03-31
GB1340407A (en) 1973-12-12
CH568269A5 (en) 1975-10-31
SU424349A3 (en) 1974-04-15
SE377561B (en) 1975-07-14
CS166750B2 (en) 1976-03-29
IE34970B1 (en) 1975-10-01
RO62244A (en) 1977-08-15
PL84395B1 (en) 1976-03-31
NO131983B (en) 1975-05-26
CS166748B2 (en) 1976-03-29
FR2081541B1 (en) 1975-01-17
AT305250B (en) 1973-02-12
CH568270A5 (en) 1975-10-31
IL36269A (en) 1974-01-14
ES388561A1 (en) 1973-05-16
BG19130A3 (en) 1975-04-30
CS166749B2 (en) 1976-03-29
AT306707B (en) 1973-04-25
SU421181A3 (en) 1974-03-25
SU404229A3 (en) 1973-10-26

Similar Documents

Publication Publication Date Title
ES423466A1 (en) 1-Aryloxy-2-hydroxy-3-alkynylamino-propanes
ES382014A1 (en) 1-cyanophenoxy-2-hydroxy-3-(cycloalkyl-amino)-propanes
ES393738A1 (en) N-(1-bicyclic aryl-propyl-2)-n'-bicyclic aryl-piperazines
ES419934A1 (en) 1-hydroxy-1-((4'-hydroxy-3'aminosulfonamido)-phenyl)-2-amino-ethanes and salts
ES385628A1 (en) Heterocyclyloxymethyl-morpholine or piperazine-derivatives
ES396175A1 (en) Phenylethanolamine derivatives
ES446701A1 (en) Biphenyl derivatives and pharmaceutical compositions thereof
ES399873A1 (en) 1-phenoxy-2-hydroxy-3-hydroxyalkylamino-propanes an processes for their preparation
ES426427A1 (en) Pharmaceutical compositions comprising nitrocarbostyrils for the treatment of allergic and immunological hypersensitivity
ES402536A1 (en) Procedure for the preparation of readanic type alkaloids. (Machine-translation by Google Translate, not legally binding)
ES432465A1 (en) Substituted 4-biphenylyl-butenoic acids esters and amides and pharmaceutical compositions containing them
ES402551A1 (en) A procedure for the preparation of piperazine derivatives. (Machine-translation by Google Translate, not legally binding)
ES393340A1 (en) Amines and a process for the manufacture thereof
ES409217A1 (en) F 5-nitroimidazole derivatives
ES379102A1 (en) A procedure for the preparation of 3-hydroxy-alpha- (aminoethyl) -bencil alcohol derivatives. (Machine-translation by Google Translate, not legally binding)
ES405281A1 (en) Cephalosporin compounds
ES387136A1 (en) Benzodiazepines the preparation thereof and compositions containing the same
ES391118A1 (en) Novel glucuronic acid derivatives and process for the preparation thereof
ES451291A1 (en) A procedure for the preparation of tienotiacin derivatives. (Machine-translation by Google Translate, not legally binding)
ES398368A1 (en) A procedure for the preparation of new derivatives of 1,2,3,4-tetrahidroisoquinoleina. (Machine-translation by Google Translate, not legally binding)
ES432477A1 (en) Procedure for the preparation of new derivatives of bifenilo. (Machine-translation by Google Translate, not legally binding)
ES389084A1 (en) A procedure to produce derivatives of benzodiazepinas. (Machine-translation by Google Translate, not legally binding)
ES363112A1 (en) A procedure for preparing benzodipirons. (Machine-translation by Google Translate, not legally binding)
ES432473A1 (en) Procedure for the preparation of new derivatives of bifenilo. (Machine-translation by Google Translate, not legally binding)
ES393339A1 (en) Naphthoquinone derivatives